Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
Mahaffey KW, Tuttle KR, Arici M, Baeres FMM, Bakris G, Charytan DM, Cherney DZI, Chernin G, Correa-Rotter R, Gumprecht J, Idorn T, Pugliese G, Rasmussen IKB, Rasmussen S, Rossing P, Sokareva E, Mann JFE, Perkovic V, Pratley R.
Mahaffey KW, et al. Among authors: idorn t.
Eur Heart J. 2024 Aug 30:ehae613. doi: 10.1093/eurheartj/ehae613. Online ahead of print.
Eur Heart J. 2024.
PMID: 39211948